Thcinol/Cbdinol Canpharma GmbH

Thcinol/Cbdinol Canpharma GmbH Overview

Thcinol/Cbdinol Canpharma GmbH is a pharmaceutical company based in Oberhavel, Brandenburg. The company operates in the German pharmaceutical market and is regulated by the BfArM (Federal Institute for Drugs and Medical Devices).

Activities & Products

Pharmaceutical companies such as Thcinol/Cbdinol Canpharma GmbH develop, produce or distribute medicines for the German and international market. All authorised products are subject to approval and are regulated by BfArM or the European Medicines Agency (EMA).

About Thcinol/Cbdinol Canpharma GmbH

Dedicated to providing the highest quality cannabis products to our wholesale and retail partners in the EU and the UK

Location & Contact

Thcinol/Cbdinol Canpharma GmbH can be reached at the following address: Wiesbadener Str. 29, 16515 Oberhavel – Phone: 030398008200. For current information and enquiries, please contact the company directly.

More information: Pharmaunternehmen in Brandenburg or all Pharmaunternehmen in Germany on Sanoliste.

Pharmazeutische Regulierung in Deutschland

Pharmaceutical companies such as Thcinol/Cbdinol Canpharma GmbH are subject to one of the world's most stringent regulatory frameworks in Germany. The German Medicinal Products Act (AMG) governs the authorisation, manufacturing, distribution and monitoring of medicinal products. Market authorisation for new active substances falls under the responsibility of either the Federal Institute for Drugs and Medical Devices (BfArM) or the European Medicines Agency (EMA), depending on whether a national or centralised authorisation is sought.

Arzneimittelversorgung & Marktumfeld

With a revenue volume exceeding 50 billion euros, the German pharmaceutical market is one of the largest in Europe. Thcinol/Cbdinol Canpharma GmbH, based in Oberhavel, is part of this market. The supply chain from manufacturer through wholesaler to pharmacy is governed by Good Manufacturing Practice (GMP) and Good Distribution Practice (GDP). Since the entry into force of the Act for Greater Safety in the Medicinal Products Supply (GSAV), stricter requirements for the traceability of medicinal products also apply.

Pharmastandort Brandenburg

Brandenburg is a significant pharmaceutical location in Germany. Companies such as Thcinol/Cbdinol Canpharma GmbH benefit from proximity to research institutions, university hospitals and well-developed infrastructure. The industry employs over 140,000 people in Germany and invests billions annually in research and development.